Results 61 to 70 of about 132,229 (258)
Introduction: Immune checkpoint inhibitors (ICIs) are increasingly being used to treat lung cancer perioperatively. Although ICI use has led to long-term improvements in patient outcomes, its high costs have increased medical expenses.
Masahiro Fujioka, MD +8 more
doaj +1 more source
SLC8A1 deficiency in colorectal cancer cells increases intracellular calcium signaling, promoting the secretion of ANXA2‐enriched small extracellular vesicles. These vesicles reprogram tumor‐associated macrophages towards an M2 phenotype, which in turn fosters a tumor microenvironment conducive to radioresistance and is associated with poor patient ...
Yimin Fang +18 more
wiley +1 more source
Background: The changes in the tumor microenvironment of high-grade serous ovarian carcinomas following neoadjuvant chemotherapy are a complex area of study. Previous research underscores the importance of investigating the immune and collagen components
Arpit Aggarwal +7 more
doaj +1 more source
Chemotherapy leverages tumor‐cell autophagy to reshape the colorectal cancer immune microenvironment. Autophagy degrades FBXW2 to promote C/EBPβ‐mediated TIMP‐2 transcription and MMP‐9 suppression, driving intra‐tumoral CD8+ T‐cell infiltration. Targeting MMP‐2/9 or restoring TIMP‐2 overcomes chemo‐resistance in autophagy‐deficient tumors. ABSTRACT The
Bing Cheng +12 more
wiley +1 more source
The value of NLR in predicting the efficacy of preoperative nimotuzumab combined with neoadjuvant chemotherapy for local advanced oral squamous cell carcinoma [PDF]
Objective To investigate the value of the peripheral blood neutrophil to lymphocyte ratio (NLR) before nimotuzumab combined with neoadjuvant chemotherapy in predicting the short-term efficacy of neoadjuvant therapy for advanced oral squamous cell ...
TIAN Liangliang, NAN Xinrong
doaj +3 more sources
Proposed model of CHST1‐associated immune remodeling in triple‐negative breast cancer. In CHST1‐low tumors, greater nuclear accumulation of NKRF is associated with repression of an NF‐κB‐related CCL20 transcriptional program and an immune‐inflamed microenvironment.
Shu‐Hao Jiang +6 more
wiley +1 more source
This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund +4 more
wiley +1 more source
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang +21 more
wiley +1 more source
To evaluate the impact of neoadjuvant chemotherapy on perioperative immune function in breast cancer patients, focusing on CD3+, CD4+, CD8+, and natural killer (NK) cells, as well as the CD4+/CD8+ ratio.
Qi-Hua Jiang +5 more
doaj +1 more source
TNFRSF19 is an epigenetically silenced regulator of mitophagy in triple‐negative breast cancer. TNFRSF19 deficiency activates the TGFBR1–SMAD3–PINK1 axis to promote mitophagy and confer doxorubicin resistance, whereas decitabine‐mediated restoration of TNFRSF19 suppresses mitophagy and enhances doxorubicin sensitivity, revealing a targetable epigenetic–
Shiyang Liu +7 more
wiley +1 more source

